DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias

Haematologica

Volumn 87, Issue 12, 2002, Pages 1324-1341

  Leone, Giuseppe ^a   Teofili, Luciana ^a   Voso, Maria Teresa ^a   Lübbert, Michael ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

5 azacytidine; Decitabine; Demethylation; Histone acetylation; Transcription modulation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5' FLUORO 2' DEOXYCYTIDINE; AMSACRINE; ANTHRACYCLINE ANTIBIOTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; CYTARABINE; DAUNORUBICIN; DINUCLEOTIDE; DNA METHYLTRANSFERASE; FAZARABINE; GEMCITABINE; IDARUBICIN; METHYLTRANSFERASE INHIBITOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALOPECIA; ANIMAL CELL; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CELL CYCLE; CHROMATIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; CYTOPENIA; DEATH; DEMETHYLATION; DNA METHYLATION; DNA MODIFICATION; DROWSINESS; DRUG FATALITY; FATIGUE; GENE EXPRESSION REGULATION; HUMAN; INFECTION; INJECTION PAIN; LEUKEMIA; MAMMAL; MEDICAL LITERATURE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCYTOPENIA; PROMOTER REGION; REVIEW; SOMNOLENCE; TUMOR SUPPRESSOR GENE; VOMITING; X CHROMOSOME;

ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS; DNA METHYLATION; DNA MODIFICATION METHYLASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY;

EID: 0036902962     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (148)

1. Singal R, Ginder GD. DNA methylation. Blood 1999; 93:4059-70.
2. Kass SU, Pruss D, Wolffe AP. How does DNA methylation repress transcription? Trends Genet 1997; 13:444-9.
3. Bartolomei MS, Tilghman SM. Genomic imprinting in mammals. Annu Rev Genet 1997; 31:493-525.
4. Nakao M, Sasaki H. Genomic imprinting: Significance in development and diseases and the molecular mechanisms. J Biochem (Tokyo) 1996; 120:467-73.
5. Panning B, Jaenisch R. RNA and the epigenetic regulation of X chromosome inactivation. Cell 1998; 93:305-8.
6. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992; 69:915-26.
7. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 1998; 58:5489-94.
8. Antequera F, Boyes J, Bird A. High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. Cell 1990; 62:503-14.
9. Laird PW, Jaenisch R. DNA methylation and cancer. Hum Mol Genet 1994; 3:1487-95.
10. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21:163-7.
11. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: Epigenetics joins genetics. Trends Genet 2000; 16:168-74.
12. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986; 321:209-13.
13. Antequera F, Bird A. Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci 1993; 90:11995-9.
14. Bird AP. Gene number, noise reduction and biological complexity. Trends Genet 1995; 11:94-100.
15. Tazi J, Bird A. Alternative chromatin structure at CpG islands. Cell 1990; 60:909-20.
16. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000; 24:132-8.
17. Gardiner-Garden M, Frommer M. CpG islands in veterbrate genomes. J Mol Biol 1987; 196:261-82.
18. Cross SH, Bird AP. CpG islands and genes. Curr Opin Genet Dev 1995; 5:309-14.
19. Baylin SB. Tying it all together: Epigenetics, genetics, cell cycle, and cancer. Science 1997; 277:1948-9.
20. Bird A. The essentials of DNA methylation. Cell 1992; 70:5-8.
21. Cedar H. DNA methylation and gene activity. Cell 1988; 53:3-4.
22. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv Cancer Res 1998; 72:141-96.
23. Herman JG Hypermethylation of tumor suppressor genes in cancer. Semin Cancer Biol 1999; 9:359-67.
24. Jones PL, Wolffe AP. Relationships between chromatin organization and DNA methylation in determining gene expression. Semin Cancer Biol 1999; 9:339-47.
25. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: Epigenetics joins genetics. Trends Genet 2000; 16:168-74.
26. Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000; 184:1-16.
27. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, et al. Silencing of the VHL tumor suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci 1994; 91:9700-4.
28. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55:4525-30.
29. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61:3225-9.
30. Wolffe AP, Pruss D. Targeting chromatin disruption: Transcriptional regulators that acetylate histones. Cell 1996; 84:817-9.
31. Jeppesen P, Turner BM. The inactive X chromosome in female mammals is distinguished by a lack of histone H4 acetylation, a cytogenetic marker for gene expression. Cell 1993; 74:281-9.
32. Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 2000; 24:88-91.
33. Nan X, Campoy FJ, Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997; 88:471-81.
34. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998; 19:187-91.
35. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998; 393:386-9.
36. Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 2000; 25:269-77.
37. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade P, Jones PL, Wolffe AP. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and repress transcription from E2F-responsive promoters. Nat Genet 2000; 25:338-42.
38. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21:103-7.
39. Issa JP, Baylin SB, Herman JG. DNA methylation changes in hematologic malignancies: Biologic and clinical implications. Leukemia 1997; 11 Suppl 1:7-11.
40. Zion M, Ben-Yehuda D, Avrahamm A, Cohenm O, Wetzler M, Melloul D, et al. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc Natl Acad Sci USA 1994; 91:10722-6.
41. Asimakopoulos FA, Shteper PJ, Krichevsky S, Fibach E, Polliack A, Rachmilewitz E, et al. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood 1999; 94:2452-60.
42. Nguyen TT, Mohrbacher AF, Tsai YC, Groffen J, Heisterkamp N, Nichols PW, et al. Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: Biological implications. Blood 2000; 95:2990-2.
43. Dhodapkar M, Grill J, Lust JA. Abnormal regional hypermethylation of the calcitonin gene in myelodysplastic syndromes. Leuk Res 1995; 10:719-26.
44. Baylin SB, Fearon ER, Vogelstein B, de Bustros A, Sharkis SJ, Burke P, et al. Hypermethylation of the 5' region of the calcitonin gene is a property of human lymphoid and acute myeloid malignancies. Blood 1987; 70:412-7.
45. Roman J, Castillejo JA, Jimenez A, Bornstein R, Gonzalez MG, del Carmen Rodriguez M, et al. Hypermethylation of the calcitonin gene in acute lymphoblastic leukemia is associated with unfavourable outcome. Br J Haematol 2001; 113:329-38.
46. INK4B. Cancer Res 1996; 56:722-7.
47. INK4A characterize the major types of hematological malignancies. Cancer Res 1997; 7:837-41.
48. INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998; 91:2985-90.
49. Roman-Gomez J, Castillejo JA, Jimenez A, Gonzales MG, Moreno F, Rodriguez MC, et al. 5' CpG Island hypermethylation is associated with transcription silencing of the p21 CIPI/WAFI/SDI1 gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 2002; 99:2291-6.
50. Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 1999; 59:3730-40.
51. Li Q, Kopecky KJ, Mohan A, Willman CV, Appelbaum FR, Weick JK, et al. Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia. Clin Cancer Res 1999; 5:1077-84.
52. Rush LJ, Dai Z, Smiraglia DJ, Gao X, Wright FA, Fruhwald F, et al. Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci Blood 2001; 97:3226-33.
53. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JPJ. Methylation profiling in acute myeloid leukemia. Blood 2001; 97:2823-9.
54. Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 1998; 19:219-20.
55. Mizuno SI, Chijiwam T, Okamura T, Akashi K, Fukumaki Y, Niho Y, et al. Expression of DNAmethyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001; 97:1172-9.
56. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002; 295:1079-82.
57. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, et al. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukemia. Nature 1998; 391:815-8.
58. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51:189-99.
59. Tuzuner N, Coxm C, Rowe JM, Watrous D, Bennett JM. Hypocellular myelodysplastic syndromes (MDS), new proposals. Br J Haematol 1995; 91:612-7.
60. Verhoef GE, Pittaluga S, De Wolf-Peeter C, Boogaerts MA. FAB classification of myelodysplastic syndromes, merits and controversies. Ann Hematol 1995; 71:3-11.
61. Michaux JL, Martiat P. Chronic myelomonocytic leukemia (CMML), a myelodysplastic or myeloproliferative syndrome? Leuk Lymphoma 1993; 9:35-41.
62. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick H, et al. The chronic myeloid leukemias, guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukemia. Proposals by the French-American-British Cooperative leukemia group. Br J Haematol 1994; 87:746-54.
63. Germing U, Gattermann N, Minning H, Heyll A, Aul C. Problems in the classification of CMML dysplastic versus proliferative type. Leuk Res 1998; 22:871-8.
64. Seymour JF, Estey EH. The contribution of Auer rods to the classification and prognosis of myelodysplastic syndromes. Leuk Lymphoma 1995; 17:79-85.
65. Gattermann N, Aul C, Schneider W. Two types of acquired idiopathic sideroblastic anaemia (AISA). Br J Haematol 1990; 74:42-52.
66. Rosati S, Mick R, Xu F, Stonys E, Le Beau MM, Larson R, et al. Refractory cytopenia with multilineage dysplasia, further characterization of an 'unclassifiable' myelodysplastic syndrome. Leukemia 1996; 10:20-6.
67. Matsuda A, Jinnai I, Yagasaki F, Kusumoto S, Minamihisamatsu M, Honda S, et al. Refractory anemia with severe dysplasia, clinical significance of morphological features in refractory anemia. Leukemia 1998; 12:482-5.
68. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835-49.
69. Nosslinger T, Reisner R, Koller E, Gruner H, Tuchler H, Nowotny H, et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: Comparison of classifications on 431 unselected patients from a single institution. Blood 2001; 98:2935-41.
70. Mufti GJ. Myelodysplastic syndromes. In: Lawson DH. Current Medicine II. Edinburgh: Churchill Livingstone; 1990. p. 19.
71. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992; 82:358-67.
72. Phillips MJ, Cull GM, Ewings M. Establishing the incidence of myelodysplasia syndrome. Br J Haematol 1994; 88:896-7.
73. Estey EH. Prognosis and therapy of secondary myelodysplastic syndromes. Haematologica 1998; 83:543-9.
74. Leone G, Mele L, Pulsoni A, Equitani F, Pagano L. The incidence of secondary leukemias. Haematologica 1999; 84:937-45.
75. Heim S. Cytogenetic findings in primary and secondary myelodysplasia. Leuk Res 1992; 16:43-6.
76. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E, et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases. Leukemia 1993; 7:1315-23.
77. Haase D, Fonatsch C, Freund M, Wörmann B, Bodenstein H, Bartels H, et al. Cytogenetic findings in 179 patients with myelodysplastic syndromes. Ann Hematol 1995; 70:171-87.
78. Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G, et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079-88.
79. Uchida T, Kinoshita T, Nagai H, Nakahara Y, Saito H, Hotta T, et al. Hypermethylation of the p15/INK4B gene in myelodysplastic syndromes. Blood 1997; 4:1403-9.
80. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/DK4. Nature 1993; 366:704-7.
81. Teofili L, Morosetti R, Martini M, Urbano R, Putzulu R, Rutella S, et al. Expression of cyclin-dependent kinase inhibitor p15(INK4B) during normal and leukemic myeloid differentiation. Exp Hematol 2000; 28:519-26.
82. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264:436-40.
83. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368:753-6.
84. INK4B) display frequent homozygous deletions in primary cells from T but not from B-cell lineage acute lymphoblastic leukemias. Blood 1994; 84:4038-44.
85. Ogawa S, Hangaishi A, Miyawaki S, Hirosawa S, Miura Y, Takeyama K, et al. Loss of cyclin-dependent kinase 4-inhibitor (p16;MTS 1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood 1995; 86:1548-56.
86. Tien HF, Tang JL, Lee CF, Jou ST. Homozygous deletion of the p16INK4A gene occurs more frequently in CD21 than in CD22 T-cell acute lymphoblastic leukemia. Blood 1998; 91:1829-30.
87. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995; 86:841-54.
88. i6INK4A) gene alternations in hematological malignancies. Leuk Lymphoma 1997; 24:449-61.
89. Uchida T, Kinoshita T, Nagai H, Nakahara Y, Saito H, Hotta T, et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndrome. Blood 1997; 90:1403-9.
90. INK4B gene in myelodysplastic syndrome, it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol 2001; 112:148-54.
91. Ben-Yehuda D, Krichevsky S, Caspi O, Rund D, Polliack A, Abeliovich D, et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 1996; 88:4296-303.
92. Das-Gupta EP, Seedhouse CH, Russell NH. Microsatellite instability occurs in defined subsets of patients with acute myeloblastic leukaemia. Br J Haematol 2001; 14:307-12.
93. Zhu YM, Das-Gupta EP, Russel NH. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood 1999; 94:733-40.
94. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002; 99:1909-12.
95. Alessandrino EP, Amadori S, Cazzola M, Locatelli F, Mecucci C, Morra E, et al. Myelodysplastic syndromes: Recent advances. Haematologica 2001; 86:1124-57.
96. Bender CM, Zingg JM, Jones PA. DNA methylation as a target for drug design. Pharm Res 1998, 15:175-87.
97. Momparler L, Cotè S, Eliopoulos N. Pharmacologica approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for therapy of leukemia. Leukemia 1997; 11 Suppl 1:1-6.
98. Santini V, Kantarajian HM, Issa JP. Changes in DNA methylation in neoplasia, pathophysiology and therapeutic implications. Ann Intern Med 2001; 134:573-86.
99. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, et al. Methylation of the 59 CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995; 55:4531-5.
100. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 1995; 92:7416-9.
101. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998; 95:6870-5.
102. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Köhler G, Wijermans P, et al. Demethylation of a hypermethylated p15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2'-deoxycytidine treatment. Blood 2002; 100:2957-64.
103. ink4b gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors. Blood 2001; 98:495-7.
104. Wijermans P, Lübbert M, Verhoef G. DNA demethylating therapy in MDS: The effect of decitabine on the platelet count. Blood 1999; 94 Suppl 1:306[abstract].
105. Creusot F, Acs G, Christman JK. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. J Biol Chem 1982; 57:2041-8.
106. Wilhelm M, O'Brien S, Rios MB, Estey E, Keating MJ, Plunkett W, et al. Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase. Leuk Lymphoma 1999; 34:511-8.
107. Sorm F, Vesely J. The activity of a new antimetabolite, 5-azacytidine, against lymphoid leukaemia in AK mice. Neoplasma 1964; 11:123.
108. Pliml J, Sorm F. Synthesis of 2'deoxy-D-ribofuranosyl-5-azacytosine. Coll Czeck Chem Commun 1964; 29:2060.
109. Taylor SM, Jones PA. Changes in phenotypic expression in embryonic and adult cells treated with 5-azacytidine. J Cell Physiol 1982; 111:187-94.
110. Christman JK, Mendelsohn N, Herzog D, Scneiderman N. Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cell (HL-60). Cancer Res 1983; 43:763-9.
111. Momparler RL. Molecular, cellular and animal pharmacology of 5-aza-2'-deoxycytidine. Pharmacol Ther 1985; 30:287-99.
112. Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Di Fiore PP. 5-Aza-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 1984; 64:922-9.
113. Jutterman R, Li E, Jaenisch R. Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 1994; 91:11797-801.
114. Covey JM, Zahardo DS. Effects of dose and duration of exposure on 5-aza-2'deoxycytidine cytotoxycity for L1210 leukemia in vitro. Cancer Treat Rep 1984; 68:1475-81.
115. Bestor TH, Verdine GL. DNA methyltransferase. Curr Opin Cell Biol 1994; 6:380-9.
116. Szyf M. Towards a pharmacology of DNA methylation. Trends Pharmacol Sci 2001; 22:350-4.
117. Attadia V. Effects of 5-aza-2'-doxycytidine on differentiation and oncogene expression in the human monoblastic leukemia cell line U-937. Leukemia 1993; 7 Suppl 1:9-16.
118. Lübbert M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies, clinical results and possible mechanisms of action. Curr Top Microbiol Immunol 2000; 249:135-64.
119. Silverman LR, Holland JF, Weinberg RS, Alter BP, Davis RB, Ellison RR, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993; 7 Suppl 1:21-9.
120. Silverman LR, Holland JF, Demakos EP. Azacytidine (azaC) in myelodysplastic syndromes (MDS), CALGB studies 8421 and 8921. Ann Hematol 1994; 68 Suppl 12:12[abstract].
121. Chitambar CR, Libnoch JA, Matthaeus WG, Ash RC, Ritch PS, Anderson T. Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes. Am J Hematol 1991; 37:100-4.
122. Rugo H, Damon L, Ries C, Linker C. Compassionate use of subcutaneous 5-azacytidine (Aza C) in the treatment of myelodysplastic syndromes (MDS). Leuk Res 1999; 23 Suppl 1:S72-5.
123. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20:2429-40.
124. nd, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A Cancer and Leukemia Group B study. J Clin Oncol 2002; 20:2441-52.
125. Zagonel V, Lo Re G, Marotta G, Babare R, Sardeo G, Gattei V, et al. 5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia, 1993; 7 Suppl 1:30-5.
126. Petti MC, Mandelli F, Zagonel V, De Gregoris C, Merola MC, Latagliata R, et al. Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients, preliminary results. Leukemia 1993; 7 Suppl 1:36-41.
127. Pinto A, Zagonel V, Attadia V, Bullian, Gattei V, Carbone, et al. 5-Aza-2'-deoxycytidine as differentiation inducer in acute myeloid leukemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant 1989; 4 Suppl 3:28-32.
128. Wijermans PW, Krulder JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5-aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997; 11:1-5.
129. Wijermans P, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M, et al. Low-Dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome, a multicenter Phase II study in elderly patients. J Clin Oncol 2000; 18:956-62.
130. Wijermans P, Verhoef G, Lübbert M. Decitabine in elderly patients with high risk MDS; an update. Blood 2002; 100 Suppl 1:355[abstract].
131. Lübbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C, et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Br J Haematol 2001; 114:349-57.
132. Lübbert M, Wijermans PW, Engelhardt M, Otto F. Acute myeloid leukemia of the elderly and frail: Hematologic and cytogenetic remission attained following repeated courses of low-dose decitabine and outpatient management. Blood 2002; 100 Suppl 1:460[abstract].
133. Issa JP, Garcia-Manero G, Mannari R, Thomas D, Giles F, Cortes J, et al. Minimal effective dose of the hypomethylating agent decitabine in hematopoietic malignancies. Blood 2001; 98 Suppl 1:2491[abstract].
134. Willemze R, Suciu S, Archimbaud E, Muus P, Stryckmans P, Louwagie EA, et al. A randomized phase II study on the effects of 5-aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia, an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia 1997; 11 Suppl 1:S24-7.
135. Fernandes MS, Schaan MD, Moschen M, Gerhardt LM, Di Leone L, et al. Decitabine (5-aza-2'-deoxycytidine, DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia, preliminary observations. Leukemia 1997; 11 Suppl 1:28-31.
136. Di Giuseppe JA, Weng LJ, Yu KH, Fu S, Kastan MB, Samid D, et al. Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells, structure-function analysis. Leukemia 1999; 13:1243-53.
137. Gore SD, Samid D, Weng LJ. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin Cancer Res 1997; 3:1755-62.
138. Rosenfeld H, Roberts J. Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-L-norleucine and acivicin in the cell culture by glutaminase-asparaginase. Cancer Res 1981; 41:1324-8.
139. Hudgins WR, Shack S, Myers CE, Samid D. Cytostatic activity of phenylacetate and derivatives against tumor cells. Correlation with lipophilicity and inhibition of protein prenylation. Biochem Pharmacol 1995; 50:1273-9.
140. Yu KH, Weng LJ, Fu S, Piantadosi S, Gore SD. Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all-trans retinoic acid. Leukemia 1999; 13:1258-65.
141. Guidez F, Ivins S, Zhu J, Soderstrom M, Waxman S, Zelent A. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARα underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 1998; 91:2634-42.
142. Breitman TR, He R. Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60. Cancer Res 1990; 60:6268-73.
143. Zhu WG, Lakshmanan RR, Beal MD, Otterson GA. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 2001; 61:1327-33.
144. Camacho L, Ryan HJ, Chanel S, Maslak P, Salomoni P, Jakubowski A, et al. Transcription modulation, a pilot study of sodium phenylbutyrate plus 5-azacytidine. Blood 2001; 98 Suppl 1:460[abstract].
145. Hassan HT, Veit A, Maurer HR. Synergistic interactions between differentiation-inducing agents in inhibiting the proliferation of HL-60 human myeloid leukaemia cells in clonogenic micro assays. J Cancer Res Clin Oncol 1991; 117:227-31.
146. Gore SD, Weng LJ, Zhai S, Figg WD, Donehower RC, Dover GJ, et al. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 2001; 7:2330-9.
147. Redner RL, Wang J, Liu JM. Chromatin remodeling and leukemia, new therapeutic paradigms. Blood 1999; 94:417-28.
148. Miller CB, Herman JG, Baylin SB, Galm O, Yerian JA, Gore SD. A Phase I dose-descalation trial of combined DNA methyltransferase (MeT)/histone deacetylase (HDAC) inhibition in myeloid malignancies. Blood 2001; 98 Suppl 1:622[abstract].